EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
Portfolio Pulse from Vandana Singh
Alzamend Neuro Inc (NASDAQ:ALZN) has received the FDA's approval to initiate a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the first patient to be dosed in Q1 2024. This will be the second indication for AL001, with the company planning to submit two more INDs by the end of 2023 for Major Depressive Disorder and PTSD. The company's CEO believes that if AL001, a next-generation lithium product, is developed, it could significantly improve current lithium-based treatments for bipolar disorder.
October 02, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alzamend Neuro Inc's stock could be positively impacted by the FDA's approval to initiate a Phase 2A clinical study of AL001 for bipolar disorder type 1.
The FDA's approval for Alzamend Neuro Inc to initiate a Phase 2A clinical study of AL001 for bipolar disorder type 1 is a significant milestone for the company. This could potentially lead to a positive impact on the company's stock as it shows progress in the company's clinical trials and potential for future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100